Search research articles
Contact Us
Filters
Showing results (451-460 of 501) with videos related to
Page
of 51
Sort By:
European Journal of Cancer (Oxford, England : 1990)
|
October 23, 2018
Anti-PD-1/PD-L1 immunotherapy in patients with solid organ transplant, HIV or hepatitis B/C infection
Martin Tio, Rajat Rai, Ogochukwu M Ezeoke, et al.
The New England Journal of Medicine
|
June 6, 2019
Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma
Caroline Robert, Jean J Grob, Daniil Stroyakovskiy, et al.
The Lancet. Oncology
|
February 11, 2014
Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study
Grant A McArthur, Paul B Chapman, Caroline Robert, et al.
European Journal of Cancer (Oxford, England : 1990)
|
April 17, 2016
Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy
Lisa Zimmer, Simone M Goldinger, Lars Hofmann, et al.
European Journal of Cancer (Oxford, England : 1990)
|
April 18, 2016
Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy
Lars Hofmann, Andrea Forschner, Carmen Loquai, et al.
Nature Medicine
|
May 16, 2023
Neoadjuvant immunotherapy for melanoma is now ready for clinical practice
Claus Garbe, Reinhard Dummer, Teresa Amaral, et al.
Journal for Immunotherapy of Cancer
|
June 7, 2020
Overall survival at 5 years of follow-up in a phase III trial comparing ipilimumab 10 mg/kg with 3 mg/kg in patients with advanced melanoma
Paolo Antonio Ascierto, Michele Del Vecchio, Andrzej Mackiewicz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 16, 2022
Prognosis of Patients With Primary Melanoma Stage I and II According to American Joint Committee on Cancer Version 8 Validated in Two Independent Cohorts: Implications for Adjuvant Treatment
Claus Garbe, Ulrike Keim, Teresa Amaral, et al.
The Lancet. Oncology
|
January 5, 2025
Neoadjuvant or perioperative therapy for melanoma metastasis in clinical practice: an international survey
Axel Hauschild, Claus Garbe, Paolo Antonio Ascierto, et al.
The Lancet. Oncology
|
April 1, 2017
Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial
Paolo A Ascierto, Michele Del Vecchio, Caroline Robert, et al.
Page
of 51
Search research articles
Search
Showing results (451-460 of 501) with videos related to
Sort By:
Page
of 51
European Journal of Cancer (Oxford, England : 1990)
|
October 23, 2018
Anti-PD-1/PD-L1 immunotherapy in patients with solid organ transplant, HIV or hepatitis B/C infection
Martin Tio, Rajat Rai, Ogochukwu M Ezeoke, et al.
The New England Journal of Medicine
|
June 6, 2019
Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma
Caroline Robert, Jean J Grob, Daniil Stroyakovskiy, et al.
The Lancet. Oncology
|
February 11, 2014
Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study
Grant A McArthur, Paul B Chapman, Caroline Robert, et al.
European Journal of Cancer (Oxford, England : 1990)
|
April 17, 2016
Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy
Lisa Zimmer, Simone M Goldinger, Lars Hofmann, et al.
European Journal of Cancer (Oxford, England : 1990)
|
April 18, 2016
Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy
Lars Hofmann, Andrea Forschner, Carmen Loquai, et al.
Nature Medicine
|
May 16, 2023
Neoadjuvant immunotherapy for melanoma is now ready for clinical practice
Claus Garbe, Reinhard Dummer, Teresa Amaral, et al.
Journal for Immunotherapy of Cancer
|
June 7, 2020
Overall survival at 5 years of follow-up in a phase III trial comparing ipilimumab 10 mg/kg with 3 mg/kg in patients with advanced melanoma
Paolo Antonio Ascierto, Michele Del Vecchio, Andrzej Mackiewicz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 16, 2022
Prognosis of Patients With Primary Melanoma Stage I and II According to American Joint Committee on Cancer Version 8 Validated in Two Independent Cohorts: Implications for Adjuvant Treatment
Claus Garbe, Ulrike Keim, Teresa Amaral, et al.
The Lancet. Oncology
|
January 5, 2025
Neoadjuvant or perioperative therapy for melanoma metastasis in clinical practice: an international survey
Axel Hauschild, Claus Garbe, Paolo Antonio Ascierto, et al.
The Lancet. Oncology
|
April 1, 2017
Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial
Paolo A Ascierto, Michele Del Vecchio, Caroline Robert, et al.
Page
of 51